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Background. Hepatitis C virus (HCV) treatment access among human immunodeﬁciency virus (HIV)/HCV-coinfected people
who inject drugs is poor, despite a high burden of disease in this population. Understanding barriers and facilitators to HCV treat-
ment uptake is critical to the implementation of new direct-acting antivirals.
Methods. We conducted in-depth interviews with patients, physicians, and social workers at an HIV treatment facility and
methadone maintenance treatment centers in Guangzhou, China to identify barriers and facilitators to HCV treatment. We included
patients who were in various stages of HCV treatment and those who were not treated. We used standard qualitative methods and
organized data into themes.
Results. Interview data from 29 patients, 8 physicians, and 3 social workers were analyzed. Facilitators and barriers were orga-
nized according to a modiﬁed Consolidated Framework for Implementation Research schematic. Facilitators included patient trust in
physicians, hope for a cure, peer networks, and social support. Barriers included ongoing drug use, low HCV disease knowledge,
fragmented reimbursement systems, HIV exceptionalism, and stigma.
Conclusions. Expanding existing harm reduction programs, HIV treatment programs, and social services may facilitate scale-up
of direct-acting antivirals globally. Improving integration of ancillary social and mental health services within existing HIV care sys-
tems may facilitate HCV treatment access.
Keywords. China; direct-acting antivirals; HCV; HIV; people who inject drugs.
Although hepatitis C infection treatment regimens have rapidly
advanced, these beneﬁts have yet to translate into improvements
in clinical outcomes and systems of care [1]. Up to 30% of
chronically infected hepatitis C virus (HCV) patients will pro-
gress to cirrhosis within 20 years, leading to end-stage liver dis-
ease and hepatocellular carcinoma [2, 3]. Hepatitis C virus has
surpassed human immunodeﬁciency virus (HIV)-related
deaths in several high-income nations [4].
Direct-acting antivirals (DAAs) have achieved over 90%
sustained virological response (SVR) rates across all genotypes
[5, 6]. Short duration, interferon-free regimens are now possible
even for patients with HIV coinfection [7]. Direct-acting antivi-
rals will not only improve SVR rates, but they also may reduce
dependence on laboratory testing and subspecialists [8]. The
World Health Organization now recommends DAAs as standard
of care for HCV [9] and that all HCV-positive adults, including
people who inject drugs (PWID), should be assessed for treatment
regardless of symptoms, ongoing drug use, or perceived disease
severity [9].Access to DAAs is an important global health priority
for low- and middle-income countries, which continue to rely on
interferon-based regimens [9]. Inone European modeling study, a
modest increase in HCV treatment rates from 8 to 15 per 1000
PWID could halve HCV prevalence within 15 years [10].
Hepatitis C virus/HIV-coinfected individuals have a 50%
higher risk of mortality than HIV monoinfected patients and
should be prioritized for treatment [9, 11]. It is unfortunate
that coinfected PWID also have the worst rates of treatment ac-
cess [12, 13]. In one study of 845 coinfected patients in the Unit-
ed States, <35% of patients eligible for treatment were referred
for HCV care, and only 0.7% of the full cohort achieved SVR [14].
Even if cost is addressed, signiﬁcant social and structural barri-
ers hinder implementation of effective care for HCV among
PWID [15–19]. Unless these barriers are reduced, scale up of
DAAs is unlikely to be successful.
National leaders have prioritized improving access to HCV
treatment in China [11], home to 30 million people living
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with HCV infection. Two thirds of PWID are HCV positive
[20], and an estimated 6% of patients enrolled in methadone
treatment are HIV/HCV coinfected (approximately 80 000 in-
dividuals) [21]. China’s large methadone treatment system
and HIV care system provide an opportunity to examine facil-
itators and barriers to HCV treatment access among coinfected
PWID. The purpose of this study was to explore social and
structural factors affecting HCV treatment access in Guang-
zhou, China in order to inform the development of strategies
for expanding access.
METHODS
Site
Our research sites included the outpatient HIV clinic at the
Guangzhou Eighth People’s Hospital (a high-volume referral
center for HIV management and treatment within the prov-
ince), the adjacent inpatient hospital, and 2 district-based meth-
adone clinics. Twenty-seven patients were recruited from clinic,
and 2 patients were admitted to the hospital for treatment of
opportunistic infections and interviewed on the ward. Field ob-
servation at clinics took place for 1 month before interviews.
Subject Recruitment
A purposive sample of HCV/HIV-coinfected PWID were re-
cruited and interviewed from October 2013 to March 2014.
We included physicians and social workers to gain a better un-
derstanding of the local social environment, but we focused on
patient narratives to develop a nonmedical perspective. Verbal
consent was obtained from all participants. All participants re-
ceived a phone card worth 100 RMB (approximately 16 US Dol-
lars [USD]) for their participation.
Interviews
A semistructured, in-depth interview guide (Supplementary 1)
was ﬁeld tested among 8 patients, 2 inpatient physicians, and
3 key informants. Trained interviewers ﬂuent in the local
language (Cantonese or Mandarin) conducted interviews in
a private location. Interview duration was 30 to 120 minutes.
Interviews were audio-recorded if consent to record was pro-
vided; if not, ﬁeld notes were taken. The interview guide in-
cluded questions regarding the patients’ experience with
HCV treatment, HCV/HIV clinical history, injection drug
use habits, and sociodemographic information. Emergent
themes were explored further in subsequent interviews until
thematic saturation was reached. We deﬁned thematic satura-
tion as the point at which further interviews did not yield new
themes or trends.
Analysis
Our methodological approach was inductive in which themes
were derived from empirical data, inﬂuenced by discourse anal-
ysis and grounded theory [22, 23] Interview transcripts were
primary sources and were translated from Chinese to English.
Transcripts were analyzed using Atlas.ti (version 7; ATLAS.ti
Scientiﬁc Software Development GmbH, Berlin, Germany).
Initial coding was undertaken by 2 independent authors after
examining 5 transcripts separately and developing a list of pre-
liminary themes. These themes were discussed at length be-
tween the 2 researchers; any discrepancies were discussed
with a third, senior investigator. The themes were then orga-
nized into a hierarchy based on their relationships with one an-
other (Supplementary 2). These themes were also tested in
subsequent participant interviews for validity. All transcribed
data was examined based on the coding book.
We analyzed the preliminary themes using an adapted ver-
sion of the Consolidated Framework for Implementation
Research (CFIR) [24]. The CFIR domains included the follow-
ing: (1) intervention characteristics, (2) individuals involved,
(3) internal environment, and (4) external environment [24].
Intervention characteristics include cost, complexity, adaptabil-
ity, sources, and evidence strength and quality. The individuals
involved embody the knowledge and beliefs about intervention,
self-efﬁcacy, individual stage of change, identiﬁcation with an
organization, and other personal attributes. The inner environ-
ment includes structural characteristics, culture, and the imple-
mentation climate. Finally, the outer environment describes
patient needs and resources, peer pressure, and external policies
and incentives. We classiﬁed the barriers and facilitators to
HCV treatment into this framework to present the hierarchy
and interrelatedness of our ﬁndings.
Institutional Review Board
This study was approved by the University of North Carolina,
Chapel Hill Institutional Review Board and the Guangzhou
Eighth People’s Hospital Institutional Review Board.
RESULTS
Interview transcripts from 29 patients, 8 physicians, and 3 social
workers were analyzed (Table 1). Four patients (14%) had under-
gone interferon-based HCV treatment. No patients had received
DAAs. Factors associated with HCV treatment access were
organized based on (1) individuals involved, (2) intervention
Table 1. Patient Population and Demographic Data
Age (Years) 27–53
Gender 28 M, 1 F
Enrolled in methadone treatment 12 (41%)
Guangzhou resident 17 (59%)
Inpatient participant 2 (6%)
Highest education level attained Elementary: 9 (31%)
Middle: 13 (45%)
High School: 6 (21%)
College: 1 (3%)
History of HCV treatment 4 (14%)
Unemployment rate 13 (45%)
Average income (USD/year) $3150
History of detention 22 (76%)
Abbreviations: HCV, hepatitis C virus; USD, US Dollars.
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characteristics, (3) inner environment, and (4) outer environ-
ment (Figure 1). Physician and social worker data generally cor-
roborated and extended patient perspectives.
Individuals Involved
Positive Patient-Physician Relationships Facilitated Treatment
Long-term patient-physician relationships facilitated engage-
ment in care. Human immunodeﬁciency virus patients formed
closer relationships with infectious disease specialists and ancil-
lary staff due to a model of HIV care that involved a multidis-
ciplinary care team, frequent follow up, and continuity of care.
As a result, HIV physicians played an important role in recom-
mending HCV treatment and setting expectations for treatment
outcomes, side effects, and adherence.
Later, my [HIV] doctor told me that my HCV viral load had
reached more than 10 million [and] that hepatitis C could
be treated [. . .] He started prescribing the medication and
I have been on hepatitis C treatment for more than a month.
– Patient, 39M, treated
Social acceptance of patients by infectious disease and substance
abuse specialists also increased trust and willingness to accept
treatment.
The infectious diseases hospitals are much better, just like
the methadone clinic. The physicians there are closer to
our type of patients.
– Patient, 38M, treated
The Hope for Cure Was a Strong Motivator for Treatment
Patients were willing to bear the ﬁnancial and physical cost of
treatment for a chance to achieve a SVR. Unlike HIV treatment,
the HCV treatment course seemed ﬁnite and allowed patients to
feel hopeful about being cured. Patients were able to plan ahead,
both ﬁnancially and emotionally.
If you want to be cured, there are no real problems, you just
need to look at your attitude. Adherence is a bit inconve-
nient, but you just need to make sure you want to be
cured. If you have a ‘waiting to die’ attitude, the outcomes
would be very different.
– Patient, 39M, treated
Ongoing Injection Drug Use Was a Perceived Disincentive for Treatment
Providers and patients believed that ongoing drug use would
have a signiﬁcant negative impact on medication compliance
and clinic follow up.
How would they have the money to get hepatitis C treat-
ment? His ﬁrst priority is drugs. These people simply do
not work. If they do not work, where does the money
come from? Even if they earn a bit, they would spend it
on drugs. How can they treat hepatitis C?
– Patient 39M, untreated
Some providers considered patients’ personal ﬁnancial and so-
cial circumstances before recommending treatment, omitting a
discussion about HCV entirely if they thought their patient was
Figure 1. Factors impacting hepatitis C virus (HCV) treatment among people who inject drugs in Guangzhou, China. HIV, human immunodeficiency virus.
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poor. Furthermore, PWID actively using drugs were mistrustful
of the medical system for fear of being identiﬁed, arrested, and
detained; these individuals were unlikely to seek care even if
diagnosed.
Characteristics of Hepatitis C Virus Treatment
The Most Pervasive Barrier to Hepatitis C Virus Treatment Access
Was Financial Cost
It’s not that people don’t want to get treated. It’s that they
don’t have the ﬁnancial means, so they are forced to give up.
– Patient, 39M, untreated
Personal poverty was a common theme, related to a history of
injection drug use, prior incarceration, HIV coinfection, and
lack of employment. Patients often relied on the government
subsistence allowance of 500–600 RMB per month (approxi-
mately 80 to 100 USD) to meet their basic living needs. In com-
parison, the cost of a full 48-week course of peg-interferon and
ribavirin cost 60 000 RMB (approximately 9600 USD).
90% of the people who got our kind of disease are relatively
poor. In general, our type of people [PWID] do not have
work for long periods of time [. . .] I have no guarantee of
basic needs such as three meals a day. How could I afford
this treatment?
– Patient, 39M, untreated
Although HIV care was provided for free for all patients, HCV
testing and treatment were not free. Supplemental insurance
(a quarterly allowance for inpatient and outpatient health
expenditures) was available only to patients registered at an
urban address. Patients often delayed treatment as they saved
money to support treatment. Many patients borrowed from
families to meet the high cost of HCV treatment.
We need to wait until we save enough money. You can’t start
treatment for one month and then stop for a month, it won’t
work . . . but I’m worried about my liver getting worse.
– Patient, 43M, untreated
Inner Environment
Structural Barriers in the Health System Affected Access
to Hepatitis C Virus Treatment
Fragmented reimbursement systems resulted in healthcare dis-
parities in which tests and treatments were covered for some pa-
tients but not for others. This resulted in delays in both
diagnosis and seeking care.
In an urban city, residents are allowed to have a free blood
test once a year. Not in rural areas. People in rural areas
usually don’t choose to go to hospital until they have a se-
vere problem.
– Patient, 47M, untreated
Furthermore, outpatient visits ranged from 3 to 8 minutes
each, with long patient wait times. A single provider could
see from 30 to 100 patients a day. Patient visits were often fo-
cused on HIV ﬁrst; discussions of HCV and treatment options
were rare.
Human Immunodeﬁciency Virus Coinfection Often Competed
With Hepatitis C Virus Care
At times, HIV infection was a direct impediment to HCV treat-
ment. National treatment guidelines stated that coinfected pa-
tients should have a CD4 count >200 to be eligible for HCV
treatment, which excluded many PWID [9, 25]. Human immu-
nodeﬁciency virus was also given higher priority than HCV,
such that healthcare delivery, funding streams, and social ser-
vices were focused on HIV, reﬂecting HIV exceptionalism [26].
As a result, healthcare needs related to HCV were often over-
shadowed, with much less disease knowledge and prioritization
for HCV.
I thought HCV, in contrast to HIV, was not a big problem.
I thought HIV treatment was more important. The fear of
HIV is much greater than HCV [. . .] there is not much
publicly available medical information.
– Patient, 40M, untreated
Furthermore, HIV-coinfected patients were seen exclusively by
HIV doctors, whereas HCV-monoinfected patients were typically
seen by hepatologists. As a result, therewere systematic differences
in the quantity and quality of HCV care. There were instances
where patients reported that physicians did not discuss their
HCV-positive diagnosis and focused solely on HIV manage-
ment. From the perspective of the physicians, some felt that
their patients would not be able to afford, tolerate, or adhere
to HCV treatment and therefore withheld the discussion.
To be honest, for those who had HIV, which is already a
heavy burden, HCV treatment will cost several tens of thou-
sands of yuan a year. Some people have the will but not the
ability. It all depends on your circumstances.
– Patient, 42M, treated
Human immunodeﬁciency virus exceptionalism resulted in
lack of information and familiarity with HCV infection.
There was pervasive uncertainty about the long-term health
consequences of chronic HCV infection, treatment length, an-
ticipated side effects, and chances for treatment success. Some
coinfected patients were not aware of their HCV status and
therefore did not seek treatment.
I had no idea about my HCV, I just knew that most drug
addicts have it.
– Patient, 41M, untreated
Decreased public awareness resulted in ambivalence about the
disease.
People don’t think treating HCV is important. They believe
HCV won’t cause harm for a long time and rarely results in
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cirrhosis . . . most patients are unwilling to treat HCV be-
cause they don’t know about it.
– Social worker, 25M
Human Immunodeﬁciency Virus Coinfection Also Facilitated Access
to Resources and Support
Patients with HIV infection could qualify for additional health-
care funds for medications and laboratory testing, as well as
social support from nonproﬁt social work organization focused
on HIV. This funding offset the cost of HCV treatment and was
an important facilitator for treatment. Additional funding could
be obtained for inpatient services for HIV-infected patents, and
physicians would sometimes admit patients to the hospital to
reduce out of pocket HCV treatment costs.
[HCV treatment] feels a bit expensive, but I am relatively
lucky, the “Red Ribbon Organization” gives me 600 RMB
subsidy every month, 3 months is 1800 RMB. Last time
I saw the doctor, I spent all of it.
– Patient, 39M, treated
Human immunodeﬁciency virus diagnosis was also an entry
point into the healthcare system, which led to an HCV diagno-
sis. Patients hospitalized with opportunistic infections were rou-
tinely tested for HCV. A positive diagnosis meant that some
patients who became medically eligible for HCV treatment
could receive it.
I thought I was young and robust, so I did not know about the
HCV until my HIV was diagnosed.
– Patient, 40M, untreated
Outer Environment
Pervasive Human Immunodeﬁciency Virus Stigma Impacted
Access to Hepatitis C Virus Treatment
We are the marginalized people, the most marginalized of
society.
– Patient, 29M, untreated
Stigma was often tied to HIV status and history of injection
drug use. Patients from rural areas reported pervasive stigma,
even refusal of medical treatment, at their local hospitals, re-
quiring them to travel long distances to ﬁnd providers willing
to take HIV-positive patients. Once outside of their area of res-
idence, however, their HCV treatment was no longer covered,
and ﬁnancial challenges prevailed. Stigma against HIV-infected
individuals reﬂected a moralistic attitude toward the disease and
drug use. This was often internalized into a tainted sense of self.
If you were walking in the street and a normal person told
you that he used to be a drug user, you would turn around
and leave, because deep down you would think, he must be a
bad guy. Even if you changed to a good guy, you are still bad.
– Patient, 29M, untreated
Stigma impacted disclosure, increased the sense of vulnerability,
and rendered patients hesitant to discuss HCV with providers.
Talking about my HCV will do little help. If I talk about it
aren’t I just exposing myself?
– Patient, 40M, untreated
Fear of disclosure among peers perpetuated ongoing HCV
transmission and decreased interest in HCV treatment, partic-
ularly if storing and injecting interferon would expose their dis-
ease status.
Social Support Promoted Awareness About Hepatitis C Virus Treatment
Patients found support among peers in the HIV clinic or the
methadone clinic. A common identity resulted in greater
trust. A peer-to-peer network, sometimes supported by formal
community-based organization (CBO) activities, was important
for disseminating information about treatment. Friends were
important resources for identifying which hospitals and provid-
ers would provide compassionate care for the patient popula-
tion. Friends and family were also important sources of moral
support.
My friend is hopeful [about being cured of HCV] because
his friends have also been through treatment and they sup-
port him.
– Patient, 39M, treated
Social workers played a critical role as well. They provided indi-
vidual and group counseling to support medication adherence,
abstinence from injection drug use, and daily attendance at
methadone clinics. Social workers also provided job counseling
to ease reintegration into employment. Social workers also
played a role in connecting previously treated patients with pa-
tients currently contemplating treatment. However, they were
also severely limited by time constraints and often traveled
long distances to cover multiple sites.
DISCUSSION
This study presents the social and structural challenges to HCV
treatment access among coinfected PWID. Other studies have
demonstrated that HCV treatment outcomes improve when so-
cial factors unique to PWID are addressed [6–8, 10]. Our study
favors acknowledgement of these social factors among PWID in
a densely populated Chinese city. These factors also play a crit-
ical role in the management of other chronic diseases among
this population, particularly in a primary care setting [27].
We found that social and peer networks facilitated HCV
treatment access. These networks ﬁlled important roles with
counseling, emotional support, linkage to community resourc-
es, and addiction recovery. This is consistent with literature
showing that nonjudgmental treatment settings with peer-led
support groups reduce stigma, facilitating treatment access
and adherence [28]. Prior studies have demonstrated the
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effectiveness of using multidisciplinary team including peers to
enhance community-based treatment programs [17, 29]. The
importance of peers in contributing to HCV treatment access
suggests that involving PWID CBOs and related groups may
improve access.
Our research suggests that HCV treatment access is facilitated
by integration with existing health delivery systems serving co-
infected PWID. Other studies have demonstrated success with
HCV treatment delivery in HIV clinics, prison health services,
and methadone maintenance programs [17, 30, 31]. These are
settings in which PWID at high risk for both HIV and HCV
are most likely to be identiﬁed, and targeted interventions
may be helpful [32].Our research is also consistent with existing
outcomes and cost-effectiveness literature showing that integra-
tion of HCV and HIV services may facilitate psychosocial sup-
port, ﬁnancial subsidies, community health worker networks,
and early monitoring of adverse effects for patients [33].
Our ﬁnding that patient-physician trust facilitated HCV
treatment access suggests that interpersonal relationships play
an important role in treatment decisions. Our interviews with
physicians corroborated this ﬁnding that longitudinal relation-
ships were important in facilitating acceptance and adherence
to medical treatment. This is consistent with research from
Australia demonstrating that trusting relationships between
HCV-positive patients and their health workers can reduce
stigma, increase healthcare service utilization, and reduce risk
behaviors [29]. Long-term physician patient relationships
allow expression of caring, concern, and compassion, which
are important aspects of trust and treatment decisions [34].
Thus, providing the time and opportunity to nurture physi-
cian-patient relationships may contribute to increased rates of
HCV treatment.
We found that poverty and high drug costs limited HCV
treatment access. Hepatitis C virus treatment costs (both
DAAs and interferon-based regimens) are prohibitive in the
absence of generic formulations and reimbursement reform.
A 12-week course of sofosbuvir currently costs approximately
84 000 USD in China, approximately 70 times the subsistence
allowance provided over the same period of time [35]. Discus-
sions have begun to include DAAs in the list of essential med-
icines, and Gilead has announced generic licensing and tiered
pricing strategies to remove barriers for treatment implementa-
tion in 91 developing countries [36, 37].However, China, Brazil,
Russia, and other middle-income countries with high burden of
HCV have been excluded from this list [35].
Finally, we found that hopefulness about cure increases mo-
tivation for testing and treatment. The development of DAAs
provides an opportunity to mobilize communities, improve
screening, and increase health-seeking behaviors. This is consis-
tent with ﬁndings from qualitative research showing that hope-
fulness for an HIV cure may increase uptake of HIV testing
[38]. As increasing numbers of HCV-positive PWID become
interested in DAA treatment, linkage to care and retention
will become critical priorities [39].
The strengths of this ﬁeldwork are its location and in-depth
focus on PWID, a large but marginalized population heavily
affected by HCV. Our study site is also a strength—Guangzhou
is a rapidly growing economy that has prioritized infectious dis-
ease research and healthcare reform, and progress here may be
emblematic of large-scale change in China. This study may pro-
vide insight into HCV treatment implementation in other mid-
dle-income countries. Our empiric ﬁndings may inform harm
reduction and HCV treatment programs in the United States,
where PWID continue to be marginalized, integration of mental
health and social interventions is poor, HIV coinfection is prev-
alent, and morbidity and mortality from HCV are on the rise.
Our study has multiple limitations. First, this is a single qual-
itative study that used purposive sampling. Broader inferences
made from these data should be made with caution. Second,
we were only able to interview 1 woman, and there may be
sex differences in treatment access [16, 40]. Third, all HCV
treatment provided to patients was interferon-based, which
may not be transferrable to DAAs. Well tolerated oral regimens
with very high rates of SVR and cure may mitigate some of the
barriers identiﬁed in our study, including concerns about side
effects, need for frequent follow up (and geographic limita-
tions), and feelings of hopelessness. When asked, all patients
unanimously agreed that a pill (ie, ribavirin) was much pre-
ferred to a needle (ie, interferon) as a route of drug administra-
tion, especially when needles were associated with intravenous
drug abuse. By extension, DAAs may have higher acceptability
and adherence rates.
However, changing the drug itself will not effect change on
systems level—cost, stigma, and marginalization of PWID will
continue to be an enormous barrier for DAAs. Middle-income
countries such as China, Brazil, Russia, Ukraine, Philippines,
and Mexico are seen as emerging markets for DAAs and were
excluded from generic licensing agreements. A report from
Médecins Sans Frontières’ estimated that 49 million individuals
living with HCV in middle-income countries were excluded
from these agreements [41].
CONCLUSIONS
Direct-acting antivirals are currently our greatest tool for control-
ling the global HCV epidemic. This feat will be possible only by
combining highly efﬁcient, well tolerated drug combinations, ac-
tive screening strategies, and improved access to care for PWID.
This study provides in-depth study of the factors impacting ac-
cess to current HCV treatment regimens. These ﬁndings may
be transferrable to other settings, and they have been corroborat-
ed by other studies in low-, middle-, and high-income countries.
Ongoing qualitative evaluation of DAA access in PWID is critical
for guiding interventions. Future policy priorities should be
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focused on addressing the speciﬁc needs of PWID and improving
linkage and retention in healthcare systems.
Supplementary Data
Supplementary material is available online at Open Forum Infectious
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